Cubist Systematic Strategies LLC Has $179,000 Position in Silence Therapeutics plc (NASDAQ:SLN)

Cubist Systematic Strategies LLC lowered its holdings in Silence Therapeutics plc (NASDAQ:SLN) by 74.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,438 shares of the company’s stock after selling 26,843 shares during the quarter. Cubist Systematic Strategies LLC’s holdings in Silence Therapeutics were worth $179,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of SLN. SG Americas Securities LLC grew its position in Silence Therapeutics by 10.5% in the 1st quarter. SG Americas Securities LLC now owns 7,000 shares of the company’s stock valued at $151,000 after purchasing an additional 667 shares during the period. Redmile Group LLC acquired a new stake in Silence Therapeutics in the 1st quarter valued at $43,798,000. Janus Henderson Group PLC acquired a new stake in Silence Therapeutics in the 1st quarter valued at $13,575,000. Lynx1 Capital Management LP lifted its stake in Silence Therapeutics by 123.4% during the 1st quarter. Lynx1 Capital Management LP now owns 526,642 shares of the company’s stock valued at $11,375,000 after acquiring an additional 290,855 shares in the last quarter. Finally, Legato Capital Management LLC bought a new position in Silence Therapeutics during the 2nd quarter valued at $376,000. Institutional investors and hedge funds own 98.73% of the company’s stock.

Silence Therapeutics Price Performance

NASDAQ SLN opened at $18.78 on Tuesday. Silence Therapeutics plc has a one year low of $6.51 and a one year high of $27.72. The business’s fifty day moving average is $18.01 and its 200-day moving average is $19.86. The stock has a market capitalization of $562.05 million, a price-to-earnings ratio of -16.19 and a beta of 1.29.

Silence Therapeutics (NASDAQ:SLN) last posted its earnings results on Thursday, August 15th. The company reported ($0.42) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10). The company had revenue of $0.76 million for the quarter, compared to analysts’ expectations of $11.28 million. Silence Therapeutics had a negative net margin of 222.44% and a negative return on equity of 58.28%. Research analysts expect that Silence Therapeutics plc will post -1.55 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on SLN. HC Wainwright restated a “buy” rating and set a $75.00 price objective on shares of Silence Therapeutics in a research note on Friday, August 30th. Jefferies Financial Group began coverage on Silence Therapeutics in a research note on Tuesday, September 3rd. They set a “buy” rating and a $40.00 price objective on the stock. Chardan Capital restated a “buy” rating and set a $55.00 price objective on shares of Silence Therapeutics in a research note on Friday, August 16th. Finally, Morgan Stanley restated an “overweight” rating and set a $49.00 price objective on shares of Silence Therapeutics in a research note on Tuesday, October 8th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $57.20.

Silence Therapeutics Profile

Silence Therapeutics plc, a biotechnology company, focuses on the discovery and development novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company's mRNAi GalNAc Oligonucleotide Discovery platform consists of precision engineered product candidates designed to target specific disease-associated genes in the liver.